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Abstract 
Purpose:  To investigate the feasibility of volumetric modulated arc therapy (VMAT) for post-
mastectomy radiotherapy (PMRT) and to compare dual-arc VMAT treatment plans to helical 
tomotherapy (HT) plans on the basis of dosimetric quality, radiobiological calculations and 
delivery efficiency.  
Methods: Dual-arc VMAT and HT treatment plans were created for fifteen patients previously 
treated at our clinic. Planning target volumes (PTV) included the chest wall and regional lymph 
nodes. The following metrics were used to compare treatment plans for each patient: dose 
homogeneity index (DHI) and conformity index (CI); coverage of the PTV; dose to organs at 
risk (OAR); tumor control probability (TCP), normal tissue complication probability (NTCP) 
and secondary cancer complication probability (SCCP); and treatment delivery time. Differences 
between treatment plans were tested for significance using the paired Student’s t-test. 
Results: Both modalities produced clinically acceptable PMRT plans. VMAT plans showed 
better CI (p < 0.01) and better OAR sparing at low doses than HT plans. For example, VMAT 
plans showed a 26% (p < 0.01) and 9% (p < 0.01) decrease in V5Gy in the lungs and heart 
respectively. On the other hand, HT plans showed better DHI (p < 0.01) and PTV coverage (p < 
0.01). HT plans also showed better sparing at higher doses for some OARs, including 8% (p < 
0.01) and 9% (p < 0.01) lower maximum doses to the lungs and heart, respectively. Both 
modalities achieved nearly 100% tumor control and approximately 1% NTCP in the lungs and 
heart, with VMAT showing lower SCCP (p < 0.01). VMAT plans also required 66.2% less time 
to deliver.  
Conclusion: Both VMAT and HT provide acceptable treatment plans for PMRT. Our study 
showed that VMAT — in addition to being significantly faster — achieved better CI and low-
dose OAR sparing while HT achieved better DHI. 
 1 
Chapter 1:  Introduction 
1.1  Background 
Breast cancer is the leading cancer diagnosis among women in the United States. An 
estimated 230,480 women were diagnosed with breast cancer in 2011 in the United States 
(Howlander et al. 2011). The most common form of breast cancer is ductal carcinoma, which can 
be located anywhere in the breast. Because breast cancer easily spreads to locoregional lymph 
nodes, approximately 40-50% of breast cancer patients undergo mastectomy (Katipamula et al. 
2009).  
First performed in 1882, the radical, or "Halsted" mastectomy involves removal of the 
entire breast, all of the axillary nodes, and the pectoralis major and minor muscles. More 
commonly performed today is the modified radical mastectomy, where the entire breast and all 
of the axillary nodes are removed, but the pectoralis muscles are left intact. Another type 
commonly performed is the simple, or "total" mastectomy. This technique involves the removal 
of the entire breast as well as the sentinel lymph nodes. The type of mastectomy performed 
depends on the stage of the cancer, the size of the tumor, the size of the breast, and the extent of 
nodal involvement. The total and modified mastectomies are illustrated in Figure 1.1. 
Figure 1.1: Total (left) and modified radical (right) mastectomy (Mastectomy. 2004, 




1.2  Post-mastectomy Radiotherapy 
After a mastectomy is performed, it is common for patients to undergo chemotherapy 
and/or post-mastectomy radiotherapy (PMRT) to eradicate any remaining subclinical disease. 
Studies have shown a significant improvement in survival for patients who underwent 
radiotherapy after surgical mastectomy (Ragaz et al. 1997; Overgaard et al. 1997; Overgaard et 
al. 1999). The National Institutes of Health currently recommends PMRT for patients with four 
or more positive axillary nodes, and/or T3 or T4 staged lesions (Eifel et al. 2001). Areas that are 
commonly treated during PMRT include the chest wall (CW), the axillary lymph nodes (AX), 
the supraclavicular lymph nodes (SC), and the internal mammary nodal chain (IMN). These 
areas make up what is called the planning target volume (PTV), an example of which is shown in 
Figure 1.2.  
1.2.1  Treatment Techniques 
PMRT has historically been treated with a conventional mixed-beam technique, which 
consists of anterior electrons to treat the medial CW and IMN, and oblique electrons to treat the 
lateral CW. The SC and AX nodes are treated with either anterior or parallel-opposed x-rays 
Figure 1.2: Skin rendering with bolus — planning target volume (PTV) highlighted in red 
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(Ashenafi et al. 2010). When two fields abut or overlap, excessing overdosing, or hot spots can 
occur. Controlling these hot spots typically requires broad beam penumbras that match at the 
50% dose level, and that have the same virtual source position. Different source positions, such 
as the beams used to treat the medial and lateral CW fields, introduces significant overlap in 
these mixed-beam plans. Additionally, the photon-electron beam junctions between the CW and 
SC fields introduce hot spots on the electron beam side, and cold spots on the photon beam side 
due to electron outscatter. One method for reducing these dose inhomogeneities is a feathering 
technique that involves shifting the field edges between fractions to smooth out the dose 
distribution. This technique, however, requires considerable effort on the part of the dosimetrist 
during planning and extra attention by the therapist during delivery. Ashenafi et al. (2010) 
showed that using helical tomotherapy for the delivery of PMRT eliminated these problems.  
1.2.1.1  Helical Tomotherapy 
Helical tomotherapy (HT) is an arc-based, photon intensity modulated radiotherapy 
(IMRT) delivery system that utilizes a rotating helical fan beam with a multi-leaf collimator 
(MLC) containing 64 binary leaf-pairs. The planning system assumes radiation is delivered at 51 
discrete projection angles. Each rotation of the gantry contains a total of up to 3264 beamlets, 
where a beamlet is the portion of the primary beam traversing one leaf pair at one projection 
angle.  illustrates HT delivery.  
Ashenafi et al. (2010) performed a treatment planning study comparing HT to 
conventional mixed-beam for PMRT. They showed that HT achieved significantly better PTV 
dose homogeneity while maintaining acceptable sparing of organs at risk (OARs). Dose 
homogeneity, as quantified by the dose homogeneity index (DHI), is a measure of the uniformity 
of dose within the PTV. They also showed, however, that HT resulted in increased dose to the 
contralateral breast as well as increased volume of tissue receiving low doses. 
 4 
 There are several other shortcomings with HT, including (1) long treatment delivery 
times, (2) limited availability of HT technology, (3) sub-optimal contrast of megavoltage 
computed tomography (MVCT) images, and (4) lack of integration with commercial oncology 
information systems. HT is only offered at a limited number of cancer centers across the United 
States. The system used for HT delivery at our clinic contains on-board imaging that uses 
MVCT, which has been shown to produce images with lower contrast than those produced with 
kilovoltage (kV) x-rays (Ruchala et al. 1999). As a result of these shortcomings, there has been 
interest in our clinic in examining the potential of volumetric modulated arc therapy (VMAT) for 
PMRT. 
1.2.1.2  Volumetric Modulated Arc Therapy 
VMAT is also an arc-based photon IMRT delivery system, but unlike HT the entire 
treatment volume can be covered by a single rotation of the gantry. Originally proposed by Yu 
(Yu 1995) as an alternative to serial tomotherapy, intensity modulated arc therapy (IMAT) 
utilized multiple coplanar arcs with constant gantry speed, constant dose rate, continuous gantry 
rotation and dynamic MLC, but each arc delivered only one level of intensity. VMAT is capable 
of varying the MLC leaf position, dose rate and gantry rotation speed simultaneously during 
Figure 1.3: Illustration of HT delivery 
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delivery (Bzdusek et al. 2009). VMAT has been described as “a treatment planning and delivery 
platform using a single 360 deg gantry arc” (Otto 2008), but our clinic has found that for more 
complex treatment sites, multiple arcs are necessary to obtain the desired dosimetric results.  
Previous studies comparing single- and multiple-arc VMAT to HT for other treatment 
sites have shown mixed results. Rong et al. (2011) reported superior dose conformity in the PTV 
with similar dose homogeneity and sparing of OARs for head and neck patients treated with 
VMAT. Another study showed HT achieved superior homogeneity, conformity, and coverage, 
with similar OAR sparing for oropharyngeal patients (Clemente et al. 2011). Rao et al. (2010) 
showed VMAT provided comparable plan quality — homogeneity, conformity and OAR sparing 
— with total treatment times up to 50% less than HT for head and neck, prostate, and lung 
patients. While these studies showed VMAT is capable of treating a variety of sites, the degree 
of benefit appears to depend on the treatment site. No studies have been published to date 
comparing these modalities for PMRT.  
1.3  Objective 
The objective of this study was to investigate the feasibility of VMAT for PMRT and to 
compare dual-arc VMAT treatment plans with HT plans on the basis of dosimetric quality, 
radiobiological calculations and delivery efficiency. Previous comparisons of VMAT and HT 
have shown no statistical advantage for either modality in OAR sparing and PTV dose 
conformity.  
1.4  Hypothesis/Specific Aims 
The hypothesis of this study is that dual-arc VMAT treatment plans and HT plans for 
PMRT with 4.98 cm field width will show no significant difference (p > 0.05) in PTV dose 
homogeneity, conformity or coverage, or in sparing of OARs, but VMAT will achieve 
significantly shorter treatment times.  
 6 
To complete this study’s objective, the following aims were performed: 
Aim 1 – Compile patient database. Fifteen PMRT patients previously treated at our clinic 
were selected and placed in a HIPAA-compliant database (Health Insurance Portability 
and Accountability Act of 1996). The following criteria were used for selection: 1) all 
patients were cared for by the same oncologist, so as to maintain consistency among the 
PTVs, 2) CT image set with PTV contour were available, and 3) all relevant anatomy was 
visible within the CT image set over the region where VMAT beams typically intersect.  
Aim 2 – Create treatment plans for VMAT and HT. All OARs were contoured. VMAT 
plans were created on Pinnacle3 v9.0 (Philips Medical Systems, Fitchburg, WI, USA) 
using the SmartArc optimization algorithm. CT and structure images were transferred to 
TomoTherapy Hi-Art v3.1.2 (TomoTherapy Inc., Madison, WI, USA) for HT planning. 
Aim 3 – Determine treatment plan evaluation metrics. Dosimetric, radiobiological and 
delivery efficiency plan evaluation metrics were applied to the plans created by both 
planning modalities. Dosimetric metrics included: mean, maximum and minimum dose to 
the PTV; dose to 95% of the PTV; dose homogeneity index (DHI) and conformity index 
(CI) for the PTV; mean and maximum dose to OARs; the volumes of lung receiving 
greater than 5, 10 and 20 Gy; the volumes of heart receiving greater than 5, 15 and 30 
Gy; and the volume of contralateral breast receiving greater than 5 Gy. Radiobiological 
metrics included tumor control probability (TCP), normal tissue complication probability 
(NTCP) for the lungs and heart, and secondary cancer complication probability (SCCP) 
for the lungs, contralateral breast and normal tissue. Delivery efficiency was evaluated on 
the basis of treatment delivery times. 
 7 
Chapter 2:  Methods 
2.1  Aim 1 – Compile Patient Database 
2.1.1  Patient Selection 
A total of 40 patients were identified as having been treated with PMRT at MBPCC 
between July 2009 and May 2011 by the same American Board of Radiology (ABR) certified 
radiation oncologist. Of these 40 patients, 35 treatment plans contained PTV contours and were 
available in either the MOSAIQ picture archival and communication system (Elekta Ltd., 
Crawley, UK), or in Pinnacle3. In many of these CT image sets, however, large volumes of 
patient anatomy were not contained within the CT field of view. Since dose cannot be calculated 
outside the image set, an accurate dose distribution cannot be determined if the beam is incident 
on the patient in these areas. This is not a concern for HT planning, as it is possible to create a 
directional-blocking structure that blocks the beam incident on the patient in this region. 
However, this is not possible in Pinnacle3, therefore those patients whose anatomy was not 
included within the CT field of view in areas where the VMAT beam typically intersect the 
patient were excluded. Of the 35 patients initially identified, 15 met all three criteria.  
2.1.2  Patient Anonymization 
Once in Pinnacle3, each patient's name, medical record number (MRN), treatment site, 
treatment modality and keywords were recorded in a HIPAA-compliant database. Each patient 
was assigned a research number of the format 11-0xx, where xx is a number from 01 to 15. In 
Pinnacle3, the patient's last name and MRN were replaced by this research number, and all other 
personally identifiable information was removed. Furthermore, the personally identifiable 
information in the image set header files was replaced by the research number or removed. 
Finally, any image sets that were not necessary for the study were removed from the treatment 
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plan data. Table 2.1 lists the cases used for this study, indicating their age, original treatment site 
and modality, and whether they received a unilateral or bilateral mastectomy.  
Table 2.1: Patient database 





11-001 52 Right CW VMAT Unilateral 
11-002 81 Left CW VMAT Unilateral 
11-003 51 Left CW VMAT Unilateral 
11-004 51 Left CW VMAT Bilateral 
11-005 35 Left CW TomoTherapy Unilateral 
11-006 53 Left CW TomoTherapy Unilateral 
11-007 60 Right CW VMAT Unilateral 
11-008 81 Right CW VMAT Unilateral 
11-009 85 Left CW VMAT Unilateral 
11-010 30 Left CW VMAT Bilateral 
11-011 76 Right CW VMAT Unilateral 
11-012 76 Left CW TomoTherapy Unilateral 
11-013 60 Right CW TomoTherapy Bilateral 
11-014 75 Right CW TomoTherapy Unilateral 
11-015 41 Right CW TomoTherapy Bilateral 
 
2.2  Aim 2 – Create Treatment Plans 
2.2.1  Contouring of Regions of Interest (ROI) 
For each patient, all existing plan information was removed except for the planning target 
volume (PTV), which was previously drawn by the radiation oncologist. All patients were 
scanned with a 1 cm thermoplastic bolus, which was used to extend the dose build-up region 
beyond the surface of the skin. This practice is also used to account for any intrafractional 
motion during treatment. The original PTV extended to the surface of the skin, and was therefore 
contracted by 0.4 cm from the right and anterior sides for a right-sided PTV, and from the left 
and anterior sides for a left-sided PTV to create a new structure, labeled “PTV”, to be used for 
optimization. The purpose of this contraction was to avoid any over-correction of intensity 
modulation in this build-up region.  
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Both lungs were contoured using Pinnacle3's Autocontour tool, which identifies regions 
based on CT thresholds. Manual edits were made where necessary. The heart, excluding the 
major vessels, was contoured from the most superior chamber to the apex. A "skin" structure was 
created using the Autocontour tool and outlined the entire patient anatomy from the superior to 
inferior boundaries of the spinal cord ROI. The contralateral breast was contoured from the 
clavicular head to the inframammary fold. The medial and lateral extents of the breast ROI were 
the CW and the surface of the skin, respectively. To ensure the contralateral breast ROI extended 
to the surface of the skin, it initially extended beyond the surface, then was contracted to the 
"skin" ROI. The entire volume of the liver visible in the CT image set was contoured. The 
airway was contoured from the base of the skull to the carina. The esophagus was contoured 
from the inferior border of the trachea to its insertion into the stomach. Finally, the spinal cord 
was contoured from the base of the skull to 5 cm inferior to the PTV. The cord was limited to 
this length so as to provide a more accurate comparison between patients who had differing 
proportions of anatomy included in the CT image set.  
Additional ROIs were created for planning purposes, including several dose-limiting 
structures, as are commonly used in our clinic. A "ring" structure is sometimes used for standard 
IMRT treatment planning to help improve conformity and achieve sharper dose falloff outside 
the PTV. Several preliminary trials were created to determine the type of ring to be used. To 
create the ring, first, two structures were created by extending the PTV by 1.0 cm and 1.5 cm. A 
third structure was created that included the area between the boundaries of the 1.5 cm and the 1 
cm structures. The resulting structure was 0.5 cm thick and surrounded the PTV with a 1.0 cm 
buffer (Figure 2.1). The described ring was determined to provide the best PTV coverage and 
homogeneity and is the configuration most commonly used at our clinic.  
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 A "normal tissue" structure including all tissue not contained in any OAR was created by 
subtracting the interior of all OARs from the skin structure. The normal tissue structure was used 
in VMAT planning but not in HT planning, as it significantly increased optimization time. A 
dose-limiting structure, labeled “limit”, was used to minimize the dose superiorly and inferiorly 
to the PTV. A directional-blocking structure, labeled “avoid”, was used in HT planning to limit 
the dose incident on the patient in regions where the patient anatomy was out of the CT field of 
view (Figure 2.2). Finally, a couch structure was used in HT planning to replace the CT couch 
with the one used during HT delivery.  
In some cases, the patient’s CT scan was performed with objects in or around the patient 
that would not be present during treatment. For example, one patient contained contrast agent in 
their stomach, which resulted in inaccurate densities in the CT data set. Each of these regions 
was contoured and their densities were manually adjusted. In cases where an object was outside 
of the patient, the density was manually set to 0.0 g/cm3 to approximate the estimated average 
Figure 2.1: "Ring" dose limiting structure helps achieve sharper dose falloff outside PTV 
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density of the surrounding air. The region in the patient containing contrast agent was manually 
set to 1.0 g/cm3 to approximate the estimated average density of the surrounding tissue. Figure 
2.3 shows an example of two such regions. 
Figure 2.2: Directional blocking structure blocks dose from entering patient through cut-off 
anatomy 
Figure 2.3: Density override structures allow treatment planning systems to ignore objects that 
will not be present during treatment 
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To maintain consistency between treatment plans, the same structures created in 
Pinnacle3 for VMAT planning were transferred to the Hi-Art planning system for HT planning. 
All ROIs — PTV, OARs and dose-limiting structures — were exported from Pinnacle3 to Hi-Art 
using Pinnacle3’s DICOM export tool (Digital Imaging and Communications in Medicine). First, 
the CT image set was exported to the Hi-Art server. In Hi-Art, the patient’s last name and MRN 
were changed to the research number, and any other personally identifiable patient information 
was removed. Finally, Pinnacle3’s DICOM export tool was used to export the “RT structures”, 
which included all ROIs created for that patient, to the Hi-Art server. 
2.2.2  Planning Setup and Parameters 
 Once the ROIs were exported to Hi-Art, the planning parameters in Pinnacle3 were set for 
VMAT planning, and those in Hi-Art were set for HT planning. Every effort was made to follow 
the standard planning procedures used at our clinic for this study.  
2.2.2.1  VMAT 
VMAT treatment plans were created in Pinnacle3 v9.0. Following the standard clinical 
procedure for PMRT at our clinic, the treatment isocenter was placed at the center of the PTV 
using the centroid placement option in Pinnacle3's Autoplace POI tool (point of interest). It was 
then manually dragged medially to approximately midway through a cross section of the lung. A 
second point, labeled “calc”, was created for use as a dose calculation point. This point was 
placed using the same method, but was dragged laterally to approximately midway through a 
cross section of the PTV. Typical locations of the “iso” and “calc” points are shown in Figure 
2.4.  
A new beam was created for an Elekta Infinity linear accelerator (Elekta Ltd., Crawley, 
UK), for a 6 MV photon dynamic arc, with the "iso" point as the isocenter of the beam. The 
beam geometry consisted of a 0 degree couch angle and a 45 degree collimator angle. Previous 
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treatment planning comparisons involving VMAT used one full gantry arc for simple cases, and 
two full arcs for more complex cases (Rao et al. 2010; Rong et al. 2011; Clemente et al. 2011). 
With the close proximity of the lungs and contralateral breast, PMRT is considered a complex 
case, thus two arcs were used for this study. A counter-clockwise gantry rotation direction, and 
initial and final arc angles of 50 and 190 degrees for right CW treatment sites. The initial and 
final arc angles for left CW treatments sites were 170 and 310 degrees. This resulted in a 220-
degree arc with boundaries intended to spare the spinal cord, contralateral breast and lungs. An 
arc for a left CW treatment is given in Figure 2.5. The dose grid was set to the default value of 
0.400 x 0.400 x 0.400 cm3 and was manually adjusted to include the entire volume of each ROI. 
The prescribed dose to the PTV was 50.4 Gy to be delivered in 28 fractions. Beam weights were 
set proportional to the dose at the "calc" point.  
The SmartArc optimization algorithm was used for VMAT treatment planning and 
optimization. This algorithm performs intensity modulation optimization at control points spaced 
Figure 2.4: Rotational isocenter (iso) and dose calculation (calc) points 
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every 24° around the arc (Bzdusek et al. 2009). These intensity maps are converted to sliding-
window MLC leaf segments, then filtered based on the number of open leaf pairs and distributed 
at 8° intervals around the arc. A second set of linearly-interpolated control points are introduced 
to meet the user specified final gantry spacing. The first set of control points undergoes machine 
parameter optimization using an iterative, nonrandomized gradient-based optimization algorithm 
(Hårdemark et al. 2004). A pencil beam dose calculation is then performed based on the singular 
value decomposition (SVD) method (Bortfeld et al. 1993). For this study, plans contained two 
arcs with 4-degree final gantry spacing and a maximum delivery time of 60 seconds per arc. A 
summary of the planning parameters used is given in Table 2.2. 
2.2.2.2  Helical Tomotherapy 
HT treatment plans were created in Hi-Art v3.1.2. A new plan was created using the CT 
dataset and ROIs imported from Pinnacle3. The standard image value-to-density table used in our 
Figure 2.5: 3D rendering of VMAT beam arc for a left CW treatment; view is from feet facing 
towards head of supine patient. PTV is shaded in red, and red lines represent VMAT 
beam delivery. 
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Table 2.2: Pinnacle3 planning parameters 
Parameter Value 
Max iterations 125 
Stopping tolerance 1x10-5 
Convolution dose iterations 30 
Apply tumor overlap fraction No 
Allow jaw motion Yes 
Constrain leaf motion 0.4 cm/degree 
Compute intermediate dose No 
Compute final dose Yes 
Fine resolution ODM No 
Final gantry spacing 4 degrees 
Maximum delivery time 60 sec/arc 
Initial gantry angle (Rt/Lt CW) 50/170 degrees 
Final gantry angle (Rt/Lt CW) 190/310 degrees 
 
clinic was used for all plans. Hi-Art considers all ROIs as one of two types: tumors, and regions 
at risk (RAR). Upon creating a new plan, all structures are initially considered as RARs. In this 
study, the PTV was converted to a tumor.  
 When two RARs overlap, Hi-Art uses the objective for the structure with the highest 
priority in any regions of overlap. The overlap priority was determined for each OAR according 
to its proximity to the PTV, with the highest priority going to the structure closest to the PTV. 
The overlap priorities in this study were: 1) Lungs, 2) Heart, 3) Contralateral Breast, 4) Liver, 5) 
Airway, 6) Esophagus, 7) Spinal Cord, 8) Ring, 9) Limit, 10) Avoid, and 11) Couch. The couch 
and normal tissue ROIs were deselected to ignore them during optimization.  
 The field width is defined as the dimension (full-width half-maximum) of the beam along 
the superior-inferior axis of the patient at the machine isocenter. Previous studies that have 
shown better dose homogeneity with HT have used a 2.5 cm field width for HT planning (Rong 
et al. 2011; Clemente et al. 2011; Rao et al. 2010), but the standard practice at our clinic is to use 
a 4.98 cm field width to reduce the delivery time of HT. Moldovan et al. (2011) reported a mean 
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increase in DHI of 0.031 when changing from 2.5 cm to 4.98 cm. Because this DHI difference is 
of similar magnitude to the reported difference in DHI between VMAT and HT treatment plans, 
no significant difference in DHI was expected in our study. 
The pitch is defined as the distance travelled by the couch per rotation of the gantry 
relative to the axial beam width and is used to determine the amount of overlap for each rotation 
of the beam. Hi-Art follows helical CT convention using the following equation for pitch: 
 . (1) 
To minimize a phenomenon known as the thread effect, recommended pitch values are multiples 
of 0.86/n, where n is an integer (Kissick et al. 2005). 0.287 was used for this study (n = 3).  
The normal grid size was used, which uses the CT image set size, down-sampled in the 
axial plane (both anterior-posterior and lateral) by a factor of 2. This resulted in a grid size of 
3.91 x 3.91 x 2.5 mm3. This is typical of HT planning due to the time-intensive nature of the 
point convolution dose calculation. 50.4 Gy was prescribed to 90% of the PTV.  
The calculation mode used for HT planning was “beamlet” mode, which performs an 
initial full dose calculation to determine the contribution of dose from each beamlet, then 
optimizes beamlet open times to meet the planning objectives. The modulation factor is the ratio 
of the maximum beam open time for any one beamlet to the average open time for all non-zero 
beamlets. A modulation factor of 3.000 was used for this study. A summary of planning 
parameters used is given in Table 2.3.  
Table 2.3: Hi-Art planning parameters 
Parameter Value 
Field width 4.98 cm 
Pitch 0.287 
Dose grid Normal (3.91 x 3.91 x 2.5 mm3) 
Calculation mode Beamlet 
Modulation Factor 3.000 
 
Pitch = Distance travelled by couch per rotation of gantry
Field width
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2.2.3  Dosimetric Planning Goals 
Dosimetric planning goals for this study were derived from normal tissue tolerances to 
therapeutic radiation published by Emami et al. (1991) and input from oncologists and 
dosimetrists at our clinic. These goals were used as a benchmark for determining clinical 
acceptability for each treatment plan. They consisted of either a maximum or minimum dose to 
an ROI, or a maximum dose to a fraction of an ROI. In general, the final planning goals listed in 
Table 2.4 reflect tissue tolerances. However, based on results from preliminary planning trials, 
they were set as low as could be achieved without degrading the dose distribution to the PTV. 
Maximum and minimum doses to each structure were defined as the dose to 1% and 99% of a 
structure respectively.  
Table 2.4: Dosimetric planning goals 
ROI Dose Volume 
PTV 
< 55 Gy 1% 
50.4 Gy 90% 
> 46 Gy 99% 
Lungs < 20 Gy 18% 
Heart < 20 Gy 18% 
Breast < 5 Gy 1% 
Liver < 15 Gy 15% 
Airway < 30 Gy 1% 
Esophagus < 30 Gy 1% 
Cord < 25 Gy 1% 
Normal Tissue < 55 Gy 1% 
 
2.2.4  Optimization and Dose Calculation 
 Optimization settings were chosen based on those commonly used at our clinic. Pinnacle3 
and Hi-Art use different optimization algorithms, therefore it was impossible to use an identical 
planning and optimization procedure for each modality. In an effort to create treatment plans that 
were both clinically relevant and objective in nature, it was necessary to define a planning 
procedure that was consistent with the common practices at our clinic as well as between VMAT 
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and HT. These procedures involved interactively adapting objectives and priorities to push the 
planning system to achieve the best plans possible.  
2.2.4.1  VMAT Optimization Procedure 
Initial optimization objectives were chosen such that the dosimetric goals could be met. 
Table 2.5 contains the initial objectives used for the VMAT plans. The PTV was assigned two 
dose objectives: 1) Uniform Dose, which attempts to keep the dose in the PTV as close to the 
prescribed value as possible, and 2) Max Dose, which attempts to keep the maximum dose to any 
one voxel in the PTV below the prescribed value. The uniform dose objective was given a target 
dose of the prescription, 50.4 Gy, while the maximum dose objective was given a target of 105% 
of the prescription, or 52.9 Gy. Each PTV objective was assigned an initial weight of 50.  
Table 2.5: VMAT initial optimization objectives 
ROI Type Target Volume Weight Type Target Weight 
PTV Uniform 50.4 Gy - 50 Max Dose 52.9 Gy 50 
Lungs Max DVH 15 Gy 15% 1 Max Dose 49 Gy 1 
Heart Max DVH 15 Gy 15% 1 Max Dose 40 Gy 1 
Breast - - - - Max Dose 2 Gy 1 
Liver Max DVH 15 Gy 10% 1 Max Dose 40 Gy 1 
Airway Max DVH 10 Gy 30% 1 Max Dose 30 Gy 1 
Esophagus Max DVH 10 Gy 50% 1 Max Dose 25 Gy 1 
Cord Max DVH 10 Gy 50% 1 Max Dose 25 Gy 1 
Ring - - - - Max Dose 50.4 Gy 1 
Normal Tissue - - - - Max Dose 30.2 Gy 1 
 
 Dose objectives used for OARs included a maximum dose objective, as previously 
described for the PTV, as well as a dose volume histogram (DVH) objective. The latter allows 
Pinnacle3 to limit the dose to a percent volume of an OAR to the target value. Both were used for 
each OAR except the contralateral breast, which, given the low maximum target dose, did not 
warrant the use of a maximum DVH objective. Dose-limiting structures were given only 
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maximum dose objectives. All OAR and dose-limiting structure objectives were assigned an 
initial weight of 1.  
To create plans using a procedure comparable to the common practice at our clinic, the 
planner was allowed to adjust the objectives and their weights after each set of iterations. These 
adjustments were made between runs. The first run consisted of 125 iterations, followed by a run 
of 75, then 50. If necessary to meet the planning goals, additional runs of 25 iterations were 
performed — typically to control hot spots in or around the PTV. The PTV objective weight was 
raised to 75 for the second run, and to 100 for all additional runs. Adjustment of the OAR and 
dose-limiting structure objectives depended on each structure’s cost function result, or objective 
value (as calculated by Pinnacle3). This value represents how well each objective is met; smaller 
numbers represent less conflict between the objective and the calculated dose to that structure. A 
composite objective value for the plan is comprised of a weighted sum of these values, and the 
optimization process involves minimizing the deviation from this value.  
After each run, if the dose to any OAR exceeded the planning goals, the weight for that 
structure was increased until the objective value was greater than 10-3. If the objective value was 
below 10-5, the target dose for that objective was reduced until the objective value was greater 
than or equal to 10-5.  
The dose-limiting structure objectives were treated differently and were used primarily to 
control hot spots, which are defined as doses of greater than 55 Gy to 1% of a structure, or cold 
spots, which are doses of less than 46 Gy to 1% of the PTV. After the first run, if hot spots 
existed in the region adjacent to the PTV, the target dose of the ring objective was decreased to 
49 Gy. If hot spots existed outside the ring, the normal tissue objective weight was increased to 
5. Following the second run, if the hot spots within the ring persisted, the ring objective weight 
was increased until the objective value was greater than 10-3. If the hot spots outside the ring 
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persisted, a new ROI was created that covered the area of the hot spot. This “hotspot” ROI was 
given a maximum dose objective with a target of 50.4 Gy and a weight that resulted in an 
objective value greater than or equal to 10-2. If after the third run the hot spots within the ring 
persisted, a new ROI was created with objectives similar to those outside the ring. At this point 
in the optimization, if all the planning goals were met, the plan was considered complete. If, 
however, there existed hot or cold spots inside the PTV, new ROIs were created surrounding 
these areas. Each was given either a minimum or maximum dose objective with a target dose of 
50.4 Gy and a weight resulting in an objective value greater than or equal to 10-2. Additional runs 
of 25 iterations were used until the hot and cold spots were reduced to meet the dosimetric 
planning goals.  
2.2.4.2  HT Optimization Procedure 
50.4 Gy at 1.8 Gy per fraction was prescribed to 90% of the PTV. Initial optimization 
objectives were set as close as possible to those used in VMAT and are listed in Table 2.6. In Hi-
Art, each ROI is assigned an overall importance as well as penalty values for each individual 
objective. The objectives for the PTV included a maximum and minimum dose of 50.4 Gy and a 
DVH dose objective ensuring 90% of the PTV received 50.4 Gy. The latter is treated as a hard 
constraint; meaning Hi-Art ensures this objective is met. Penalties for both PTV objectives were 
set to 1000, while the overall importance for the PTV was set to 300. Unlike those for the PTV, 
the DVH dose objectives for the ROIs are not hard constraints. The OARs and dose-limiting 
structures were each given an initial importance of 30 and 1 respectively. During preliminary 
trials, the contralateral breast proved difficult to meet its dosimetric goal with this initial 
importance, therefore it was given an initial importance of 100. The maximum and minimum 
dose penalties for the OARs were either 1 or 10, depending on which objective was more closely 
 21 
related to the final dosimetric goal for that organ. All penalties for the dose-limiting structures 
were set to 1.  












Lungs 30 49 Gy 1 15% 15 Gy 10 
Heart 30 40 Gy 1 15% 15 Gy 10 
Breast 100 2 Gy 10 50% 1 Gy 1 
Liver 30 40 Gy 1 10% 15 Gy 10 
Airway 30 30 Gy 1 30% 10 Gy 10 
Esophagus 30 25 Gy 10 50% 10 Gy 1 
Cord 30 25 Gy 10 50% 10 Gy 10 
Ring 1 30.2 Gy 1 50% 30.2 Gy 1 
Limit 1 16.8 Gy 1 50% 16.8 Gy 1 
Avoid 1 1 Gy 1 1% 1 Gy 1 
 
 The objectives were interactively adjusted to produce the best plan for each patient. After 
the initial full dose calculation to determine the contribution of dose from each beamlet, 
optimization commenced. After 30 iterations, the optimization was paused and, working with 
three OARs at a time, their penalties were increased by a factor of 10. Optimization then 
resumed for 20 iterations, after which penalties were increased by another factor of 10 (if 
necessary), and optimization resumed for 20 iterations. After two consecutive increases in 
penalties the importance was increased by a factor of either 3.3 or 3.0 (30, 100, 300, 1000, 
etc…). The optimization resumed for sets of 20 iterations. Alternating between increasing 
penalties and importance, the adjustment process was repeated until the dosimetric goals were 
met for these OARs. After each OAR’s goal was met, the objectives for another OAR were 
adjusted using the same method. This process continued until all dosimetric goals were met. If at 
any point during the process a change caused the DVH of the PTV to be degraded by greater 
than 1 Gy or to exceed the planning goals, the method described above was used to increase the 
importance and penalties for the PTV.  
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 Once the goals for all OARs were met, or after 150 iterations, the PTV penalties were 
increased and the PTV importance was reduced, each by a factor of 10. The high penalties 
worked to maintain the DVH of the PTV, while the reduced importance allowed sparing of 
OARs to be pushed to lower doses. Optimization resumed for just ten iterations, then the PTV 
importance was raised by a factor of 3 or 3.3. At this point, the target doses for each OAR were 
decreased to approximately 3 Gy less than the values currently being met. If a target dose for 
either a DVH or max dose objective was at least 3 Gy below the dose to that OAR, the target 
dose was not adjusted. Optimization resumed for 20 iterations, then the PTV importance was 
raised by another factor of 10. Additional sets of 20 iterations were performed, between which 
the OAR target dose adjustments were repeated until a minimum of 250 iterations were 
completed and no further reduction in dose to the OARs was possible without degrading the dose 
to the PTV.  
A full dose calculation was performed; the number of fractions changed to 28, and a final 
dose calculation was performed. Since Hi-Art does not have the capability to manually normalize 
the plan so that exactly 90% of the PTV receives the prescription dose after the final dose 
calculation, the percentage in the prescription was adjusted, optimization resumed for five 
iterations, and the full dose and final dose calculations were repeated until 90 ± 2% of the PTV 
was receiving 50.4 Gy.  
To compare HT and VMAT plans, patient data from the HT plans were archived and 
their dose distributions imported into Pinnacle3 using an in-house dose-extraction script. This 
script extracts the location and magnitude of the maximum dose point in the HT plan and places 
an image file containing this point and the dose distribution relative to this point in a temporary 
folder. These image files are used to import the HT dose distribution to a separate plan trial in 
Pinnacle3. It is necessary to match the dose grid from the imported plan to that of the CT set in 
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Pinnacle3. The location and magnitude of the maximum dose point in the imported plan are 
verified against the output of the dose-extraction script. Finally, the percent volume of the PTV 
receiving the prescription dose in the VMAT plan was normalized to that of the HT plan.  
2.3  Aim 3 – Determine Treatment Plan Evaluation Metrics 
2.3.1  Dosimetric Plan Evaluation Metrics 
 RTOG (Radiation Therapy Oncology Group) protocol files were exported from Pinnacle3 
for each plan to be evaluated. The dosimetric evaluation metrics used to compare the two plans 
were the following:  
1. Mean, maximum and minimum doses to PTV 
2. Dose to 95% of PTV 
3. Dose Homogeneity Index (DHI) 
4. Conformity Index (CI) 
5. Mean and maximum doses to lungs, heart, contralateral breast and normal tissue 
6. Volumes of lungs receiving greater than 5, 10 and 20 Gy  
7. Volumes of heart receiving greater than 5, 15 and 30 Gy 
8. Volume of contralateral breast receiving greater than 5 Gy 
Mean, maximum and minimum doses (Dmean, Dmax and Dmin) were extracted from DVH 
data in RTOG protocol files using an in-house radiotherapy plan evaluation tool (RPET) written 
in MATLAB (MathWorks Inc.). Maximum and minimum dose to an ROI was defined as the 
dose to 1% and 99% of each ROI respectively. This formalism was chosen to ignore small, 
clinically-insignificant hot or cold spots that may appear due to dose algorithm approximations. 
The dose to 95% of the PTV (D95%) was used to quantify PTV coverage.   
 Uniformity of dose within the PTV was evaluated using the dose homogeneity index 
(DHI) as described by Lee et al. (2008), and is calculated as: 
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 , (2) 
where Dmax and Dmin represent the dose to 1% and 99% of the PTV respectively, and Dprescribed is 
the prescription dose. Smaller values represent increasing dose homogeneity, with a value of 0 
being ideal.   
 Dose conformity in the PTV was evaluated using the conformity index (CI) described by 
Paddick (2000). CI, a measure of how well the volume of a prescribed isodose value conforms to 
both the size and shape of the PTV, is calculated as: 
 , (3) 
where TV is the target volume, PIV is the volume of the prescribed isodose value and TVPIV is the 
volume of the target that is covered by the prescribed isodose value. The isodose value used for 
this calculation was the prescription dose, 50.4 Gy. Larger values of CI represent increasing dose 
conformity, with a value of 1 being ideal.  
The percent volume of the lungs receiving greater than 20 Gy (V20Gy) is considered to be 
a useful parameter in comparing treatment plans to evaluate the risk of pneumonitis (Graham et 
al. 1999). Studies have also shown that doses below 30 Gy to the heart shows no increase in 
cardiac mortality (Gagliardi et al. 1996; Gagliardi et al. 1998; Eriksson et al. 2000). Hence, 
V20Gy in the lungs, and V30Gy in the heart were compared. V5Gy and V10Gy in the lungs, and V5Gy 
and V15Gy in the heart were also compared. 
2.3.2  Radiobiological Plan Evaluation Metrics 
RPET was also used to calculated the following radiological plan evaluation metrics:  
1. Tumor control probability (TCP) 
2. Normal tissue complication probability (NTCP) for the lungs and heart 
3. Secondary cancer complication probability (SCCP) for the lungs, contralateral breast 













TCP was calculated using the model described by Brenner (1993). TCP for the entire 
PTV is the product of control probabilities for each sub volume i of the differential DVH:  
 , (4) 
and 
 !"#! = !!!×!"!, (5) 
where N is the initial number of clonogenic tumor cells and is calculated as the product of the 
tumor cell density, n, and the volume of the PTV: 
 . (6) 
A wide range of tumor cell densities have been reported for use in TCP models (Webb & Nahum 
1993; Wigg 2001; Strigari et al. 2008). The most common value reported by Wigg (2001) for 
breast tissue (n = 107 cm-3) was used for this study. SFi is the survival fraction calculated using 
the linear-quadratic model for cell survival: 
 , (7) 
where ! and ! represent the rate of lethal and sublethal DNA damage production respectively, 
and G is a quantity dependent on the fractionation scheme and the half-time for sublethal damage 
repair. For x well-separated fractions, G = 1/x. Table 2.7 contains the parameters used to 
calculate TCP.  
Preliminary results for TCP were significantly lower in the VMAT plans. Pinnacle3 does 
not calculate dose to air, therefore any region of the PTV that extended into air was counted as 
receiving no dose. Hence, these areas were removed from the PTV for use in TCP calculations. 
Table 2.7: Parameters used to calculate TCP 
Parameter Value Source 
! 0.51 Gy-1 Wigg 2001 
! 0.061 Gy-2 Wigg 2001 
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NTCP for the lungs was calculated using the LKB probit model (Lyman 1985; Kutcher & 
Burman 1989; Burman et al. 1991), with radiation pneumonitis as an endpoint: 
 , (8) 
where 
  (9) 
and 
 , (10) 
where v is the fractional volume irradiated to a uniform dose D, m models the steepness of the 
dose-response curve, n models the volume effect, and TD50 is the dose producing a 50% 
complication rate for uniform irradiation of a whole volume. Values can be found for 
homogeneous dose distributions, but distributions in the lung were inhomogeneous in this study. 
Treatment plan DVHs were therefore reduced to equivalent uniform irradiation using the 
effective volume method (Kutcher & Burman 1989). The effective volume is calculated using 
 , (11) 
where vi is the fractional volume of sub volume i, and di is the dose per fraction to sub volume i. 
When this effective volume is used for v, the maximum dose to the entire volume, Dmax, can be 
substituted for D in equation (9). Table 2.8 contains the parameters used to calculate NTCP for 
the lungs. 
Table 2.8: Parameters used to calculate NTCP for the lungs 
Parameter Value Source 
m 0.18 Burman et al. 1991 
n 0.87 Burman et al. 1991 


























NTCP for the heart was calculated using the relative seriality model (Källman et al. 
1992), with an endpoint of cardiac mortality due to ischemic heart disease. This is a Poisson 
based statistical model of cell survival: 
 , (12) 
where n is the number of sub volumes in the DVH, vi is the fractional volume of each sub 
volume i and s is the relative seriality of the organ. Relative seriality is defined as the ratio 
between the number of serial functional subunits to the total number of functional subunits. P(Di) 
is the complication probability of a sub volume receiving dose Di, and is given by 
 , (13) 
where ! is the maximum slope of the dose-response curve and TD50 is the dose producing a 50% 
complication rate. Table 2.9 contains the parameters used to calculate NTCP for the heart. 
Table 2.9: Parameters used to calculate NTCP for the heart 
Parameter Value Source 
s 1.0 Gagliardi et al. 1996 
! 1.28 Gagliardi et al. 1996 
TD50 52.3 Gy Gagliardi et al. 1996 
 
SCCP was calculated for the lungs, contralateral breast and normal tissue using the 
Schneider model (Schneider & Kaser-Hotz 2005; Schneider et al. 2005): 
 , (14) 
where Inorg is the absolute cancer incidence for an organ in percent per gray. Reported values of 
Inorg represent lifetime risk, and assume a residual life expectancy of 50 years. Any age 
dependent effect of radiation-induced breast cancer was ignored. OEDorg is the organ equivalent  









































where i is the dose calculation point, N is the number of calculation points in the organ and ! is 
the cell sterilization parameter. OEDorg represents the corresponding dose in gray for an 
inhomogeneous dose distribution, which if distributed evenly throughout the organ, causes the 
same radiation-induced cancer incidence.  
Inorg was estimated using atomic bomb survivor data and applies to whole-body 
irradiation. Because the CT sets for these patients were limited to partial body scans, the SCCP 
for normal tissue was reduced by the ratio of the volume of normal tissue to the volume of an 
average woman. This average-woman volume was calculated using the average weight, 74.7 kg, 
of women between the ages of 20 and 74 (Ogden et al. 2004), and an estimated average density 
of 0.001 kg/cm3. Table 2.10 contains parameters used to calculate SCCP.  
Table 2.10: Parameters used to calculate SCCP 
Organ ! Inorg Source 
Lungs 0.085 Gy-1 1.68% Gy-1 Schneider & Kaser-Hotz 2005 
Contralateral Breast 0.085 Gy-1 0.78% Gy-1 Schneider & Kaser-Hotz 2005 
Normal Tissue 0.085 Gy-1 1.76% Gy-1 Schneider & Kaser-Hotz 2005 
 
2.3.3  Delivery Efficiency 
Delivery efficiency was evaluated by comparing the actual treatment delivery time for 
each plan. VMAT plans were exported from Pinnacle3 to MOSAIQ and delivered using an 
Elekta Infinity clinical linear accelerator. Each plan was delivered twice, and an average delivery 
time was reported. HT delivery time was taken from the Hi-Art plan report, which contains an 
accurate estimate of delivery time for each patient.  
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Chapter 3:  Results 
Differences were noted between those patients who received a unilateral mastectomy and 
those who received a bilateral mastectomy; therefore one patient representative of each group are 
presented here. Results are presented in the following order: 
1. Isodose distribution comparison 
2. DVH comparison 
3. Dosimetric and radiobiological results for the PTV 
4. Dosimetric and radiobiological results for the lungs, heart, contralateral breast and 
normal tissue 
5. Delivery efficiency 
Figures containing isodose distributions for each patient are presented for transverse CT 
slices in two planes through the PTV: the first containing the VMAT beam isocenter and the 
second in the supraclavicular region. The PTV is shaded red in each image, and the color coding 
of isodose lines displayed is listed in Table 3.1.  
Table 3.1: Color Coding for Isodose Distributions and DVHs 
Isodose or ROI Color 
55.0 Gy Yellow 
52.9 Gy Green 
50.4 Gy Blue (thick) 
45.4 Gy Sky blue 
35.0 Gy Orange 
25.0 Gy Forest green 
15.0 Gy Purple 




Contralateral Breast Orange 
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Note that dose to air outside the patient is set to zero in Pinnacle3 but is calculated in Hi-
Art, therefore the dose distributions for the HT plans show isodose lines extending into the air 
around the patient. Figures containing DVHs include the PTV, lungs, heart and contralateral 
breast for each modality; the color codings are given in Table 3.1. DVHs for the VMAT plans 
are displayed as solid lines, and for the HT plans are displayed as dashed lines. These graphs 
show the percentage of the total volume (y-axis) of each region of interest receiving a specified 
dose (x-axis) in units of Gy.   
3.1  Patient 11-003 
Patient 11-003 was a 51-year-old woman diagnosed with invasive ductal carcinoma of 
the upper-outer quadrant of the left breast. After receiving a left modified radical mastectomy, 
she received PMRT of the left CW using VMAT.  
3.1.1  Isodose Distribution Comparison 
Isodose distributions for the VMAT (Figure 3.1a) and HT (Figure 3.1b) plans are shown 
for a transverse slice through the plane containing the VMAT beam isocenter. The yellow line 
shown in the sagittal slice (Figure 3.1c) delineates the location of the transverse plane.  
The VMAT plan contained a fairly large region in the PTV receiving greater than 105% of the 
prescription dose, 52.9 Gy. This was not the case in the HT plan, as the dose distribution within 
the PTV was more homogeneous. There were hot spots (doses greater than 55 Gy) in the lateral 
portion of the PTV in the VMAT plan and in the medial portion of the PTV in the HT plan. 
However, these volumes did not exceed the planning goal of less than 55 Gy to 1% of the 
volume and were therefore considered to be clinically acceptable. The distributions showed 
comparable PTV dose coverage between the two modalities; however, the prescription isodose 
line in the HT failed to include part of the PTV near the lung.   
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 PTV conformity in the HT plan appeared worse than in VMAT; a region posterior to the 
lateral portion of the PTV in the HT plan received 50.4 Gy or greater. The 15 and 25 Gy lines 
extended farther into the major vessels of the heart in the HT plan than in VMAT. The 5 Gy line 
extended farther through the patient in the HT plan than in VMAT.  
 Figure 3.2 shows isodose distributions for the VMAT (Figure 3.2a) and HT (Figure 3.2b) 
plans in a transverse slice through a plane in the supraclavicular region of the PTV. The yellow 
line shown in the sagittal slice (Figure 3.2c) delineates the location of the images.  
Figure 3.1: Isodose distributions for patient 11-003 showing VMAT (a) and HT (b) plans in 
transverse slice — designated by yellow line in sagittal view (c) — containing VMAT 
beam isocenter 
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 Similar to the slice through isocenter, the VMAT plan contained a fairly large region of 
the PTV receiving greater than 105% of the prescription, while the HT plan achieved a more 
uniform dose distribution in the PTV on this slice. There was a small hot spot near the lateral 
corner of the PTV in the VMAT plan, but the volume of this region was less than 1% of the PTV 
and was therefore considered to be clinically acceptable.  
 Once again there was a small region posterior to the PTV in the HT plan receiving 50.4 
Gy or greater, resulting in what appeared to be greater PTV dose conformity in the VMAT plan. 
Figure 3.2: Isodose distributions for patient 11-003 showing VMAT (a) and HT (b) plans in 
transverse slice — designated by yellow line in sagittal view (c) — located in 
supraclavicular region 
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Consistent with the HT plan in the slice through isocenter, the prescription isodose line extended 
farther toward the surface of the PTV, and the 5 Gy isodose line extended farther through the 
patient.  
3.1.2  DVH Comparison 
Figure 3.3 contains a DVH for the VMAT and HT plans for patient 11-003. The 
“shoulder” of a DVH, specifically for the PTV, is the region where the curve bends away from 
100%. The “falloff” is the region after the shoulder in which the curve maintains a constant 
slope. The VMAT plan contained a broader shoulder in the PTV, suggesting inferior dose 
coverage compared with HT. The PTV had a sharper falloff in the HT plan representing the 
superior PTV dose homogeneity seen in the isodose distributions.  
The HT plan showed a smaller volume of the lung receiving greater than approximately 





















Figure 3.3: DVH for patient 11-003 
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trend was seen in the heart, where above 30 Gy the results were comparable, but VMAT 
achieved smaller low-dose volumes. The contralateral breast showed comparable results between 
the two modalities.  
3.1.3  PTV 
Results for the PTV are shown in Table 3.2. The HT plan showed better dosimetric 
results in the PTV in almost every metric for patient 11-003. The HT plan achieved lower mean 
and maximum doses to the PTV. PTV dose coverage, as measured by the minimum dose and the 
dose to 95% of the volume, was higher in the HT plan. The HT plan also showed a more 
homogeneous dose distribution in the PTV, achieving a DHI of 0.085 compared with 0.161 in 
the VMAT plan. However, the VMAT plan showed higher CI than HT. This is most likely due to 
the volume posterior to the PTV in the HT plan receiving greater than 50.4 Gy. TCP calculations 
showed nearly 100% control for both modalities. 













VMAT 52.4 ± 1.6 54.8 46.7 49.5 0.773 0.161 99.9 
HT 51.3 ± 0.8 53.4 48.6 50.1 0.700 0.085 100.0 
 
3.1.4  Lungs 
Table 3.3 shows the results for the lungs. The maximum dose and V20Gy in the lungs were 
lower in the HT plan. However, as shown in Figure 3.3, a much larger percentage of the volume 
of the lungs received low doses in the HT plan. 93.2% of the lungs received at least 5 Gy in the 
HT plan, while only 58.1% received this dose in the VMAT plan. Similarly, 40.8% of the lungs 
received greater than 10 Gy in HT, while only 29.9% received this dose in VMAT. 
Consequently, the VMAT plan resulted in a lower mean dose and SCCP in the lungs. The plans 
resulted in comparable values for NTCP.  
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VMAT 11.0 49.0 58.1 29.9 15.7 0.2 5.1 
HT 12.4 44.3 93.2 40.8 14.0 0.4 6.2 
 
3.1.5  Heart 
Results for the heart are shown in Table 3.4. V30Gy in the heart was lower in the VMAT 
plan. The maximum dose to the heart was lower in the HT plan, which received a dose of 40.8 
Gy compared with a maximum of 44.1 Gy in VMAT. Similar to the lungs and as shown in 
Figure 3.3, a larger percentage of the volume of the heart received low doses in the HT plan. The 
entire heart received greater than 5 Gy in the HT plan, while only 91.1% received this dose in 
VMAT. Similarly, 36.6% of the heart received greater than 15 Gy in the HT plan, while only 
25.7% received this dose in VMAT. The mean dose to the heart was only 12.9 Gy in the VMAT 
plan compared with 16.2 Gy in HT. The plans resulted in comparable values for NTCP.  














VMAT 12.9 44.1 91.1 25.7 6.8 1.5 
HT 16.2 40.8 100.0 36.6 7.5 1.3 
 
3.1.6  Contralateral Breast 
The results for the contralateral breast are given in Table 3.5. The two modalities showed 
comparable results. The VMAT plan achieved a lower mean dose to the breast. 0.1% of the 
volume received greater than 5 Gy in the HT plan, but since the maximum dose to the structure 
was defined as the dose to 1% of the volume, the maximum dose to the breast was only 3.3 Gy, 
which was lower than the maximum dose of 3.5 Gy in VMAT. Both modalities resulted in 
approximately 1% SCCP.  
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VMAT 1.2 3.5 0.0 0.8 
HT 1.5 3.3 0.1 1.0 
 
3.1.7  Normal Tissue 
Table 3.6 shows the results for the normal tissue, where the VMAT plan showed better 
results in each metric. The mean dose was 8.1 Gy in the VMAT plan and 12.7 Gy in the HT plan, 
and the maximum dose was 42.4 Gy in the VMAT plan and 46.8 Gy in the HT plan. The 
calculated value for SCCP was also lower in the VMAT plan.  








VMAT 8.1 42.4 0.9 
HT 12.7 46.8 1.0 
 
3.1.8  Delivery Efficiency 
VMAT was able to deliver this treatment plan approximately three times faster than HT. 
Using two arcs with 220-degrees of rotation each, the VMAT plan delivery time for patient 11-
003 was an average of 130.5 ± 1.6 s compared with 391.9 s for the HT plan.   
3.2  Patient 11-013 
Patient 11-013 was a 60-year-old woman diagnosed with invasive carcinoma of the 
upper-outer quadrant of the right breast. After receiving a bilateral modified radical mastectomy, 
she received PMRT of the right CW using HT. 
3.2.1  Isodose Distribution Comparison 
Isodose distributions for the VMAT (Figure 3.4a) and HT (Figure 3.4b) plans are shown 
for a transverse slice through the plane containing the VMAT beam isocenter. The yellow line 
shown in the sagittal slice (Figure 3.4c) delineates the location of the transverse plane.  
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Both modalities produced treatment plans with a high degree of dose homogeneity within 
the PTV. The VMAT plan showed a small spot receiving greater than 52.9 Gy in the medial 
portion of the PTV. This was not the case in the HT plan, but there was a small spot in the center 
of the PTV receiving less than the prescription dose. The distributions showed comparable PTV 
dose coverage and conformity between the two modalities. The 15 and 25 Gy isodose lines 
extended farther into the posterior portion of the patient, and the 5 Gy line extended farther 
through the entire patient in the HT plan. 
Figure 3.4: Isodose distributions for patient 11-013 showing VMAT (a) and HT (b) plans in 
transverse slice — designated by yellow line in sagittal view (c) — containing VMAT 
beam isocenter 
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 Figure 3.5 shows isodose distributions for the VMAT (Figure 3.5a) and HT (Figure 3.5b) 
plans in a transverse slice through a plane in the supraclavicular region of the PTV. Similar to the 
slice through isocenter, both modalities showed a high degree of dose homogeneity within the 
PTV. There was a small spot receiving greater than 52.9 Gy near the medial corner of the PTV in 
the VMAT plan. The HT plan contained regions in the medial portion of the PTV receiving less 
than and posterior to the PTV receiving greater than the prescription dose. This suggests the PTV 
dose coverage and conformity in the HT plan was inferior to that of VMAT. Once again, the 5 
and 15 Gy isodose lines extended farther through the patient in the HT plan.  
Figure 3.5: Isodose distributions for patient 11-013 showing VMAT (a) and HT (b) plans in 
transverse slice — designated by yellow line in sagittal view (c) — located in 
supraclavicular region 
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3.2.2  DVH Comparison 
Figure 3.6 shows DVHs for VMAT and HT plans for patient 11-013. The VMAT and HT 
plans contained nearly identical DVHs for the PTV with a very narrow shoulder and sharp 
falloff, representing a high degree of dose homogeneity within the PTV as seen in the isodose 
distributions. 
The plans showed comparable results at higher doses to the lungs and heart, but doses 
below approximately 13 Gy in the VMAT plan were delivered to smaller volumes. However, 
smaller volumes received doses between approximately 13 and 30 Gy in the HT plan. There is 
no DVH for a contralateral breast as this patient received a bilateral mastectomy prior to PMRT.  
3.2.3  PTV 
Results for the PTV are shown in Table 3.7. There was very little difference between the 




















Figure 3.6: DVH for patient 11-013 
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achieved comparable DHI, mean and maximum doses, and similar coverage. However, the 
VMAT plan showed higher CI compared with HT. This is evident in Figure 3.5b where the HT 
plan shows areas inside the PTV receiving less than, and outside the PTV receiving greater than 
the prescription dose. Both modalities achieved 100% tumor control.  













VMAT 51.1 ± 0.8 52.5 48.3 49.7 0.805 0.084 100.0 
HT 51.2 ± 0.9 52.7 48.3 49.7 0.709 0.087 100.0 
 
3.2.4  Lungs 
Table 3.8 shows the results for the lungs. Mean dose was lower in VMAT, but maximum 
dose was lower in HT. V20Gy in the lungs was lower in the HT plan; however, as shown in Figure 
3.6, a larger percentage of the volume of the lungs received low doses in the HT plan. 98.9% of 
the lungs received at least 5 Gy in the HT plan, while only 78.1% received this dose in the 
VMAT plan. Similarly, 48.5% of the lungs received greater than 10 Gy in the HT plan, while 
only 36.3% received this dose in the VMAT plan. Consequently, the VMAT plan resulted in a 
lower mean dose to the lungs as well as lower values for NTCP and SCCP.  
















VMAT 12.0 45.6 78.1 36.3 16.2 0.3 5.7 
HT 13.3 44.7 98.9 48.5 15.6 0.7 6.3 
3.2.5  Heart 
Results for the heart are shown in Table 3.9. The maximum dose to the heart was much 
higher in the HT plan, which received a maximum 42.2 Gy compared with 28.4 Gy in VMAT. 
V30Gy in the heart was approximately the same in both plans; however, as shown in Figure 3.6, 
the volume of the heart receiving between approximately 13 and 30 Gy was lower in HT. Nearly 
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the entire heart received greater than 5 Gy in both plans, and the mean dose to the heart was 
lower in the VMAT plan. The calculated NTCP was 0.1% for both treatment plans.  














VMAT 11.6 28.4 97.6 19.4 0.5 0.1 
HT 12.4 42.2 100.0 15.9 0.7 0.1 
 
3.2.6  Normal Tissue 
Table 3.10 shows the results for the normal tissue, where the VMAT plan showed better 
results in each metric. The mean dose was 6.5 Gy in the VMAT plan and 10.1 Gy in the HT plan. 
The maximum dose was 40.5 Gy in the VMAT plan and 42.2 Gy in the HT plan. The lower 
mean and maximum doses in the VMAT plan resulted in a lower SCCP, but the calculated value 
for both plans was less than 1%.  








VMAT 6.5 40.5 0.6 
HT 10.1 42.2 0.8 
 
3.2.7  Delivery Efficiency 
Similar to patient 11-003, the VMAT plan was able to deliver treatment approximately 
2.7 times faster than HT. The VMAT plan delivery time for patient 11-013 was an average of 
130.5 ± 1.2 s compared with 358.6 s for the HT plan.   
3.3  Overview of All Patients 
Results for all patients are presented here. Mean values (± 1!mean) are given for each 
metric. Statistical significance was determined for each comparison using the paired, two-tailed 
Student’s t-test with a significance level of p = 0.05.  
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3.3.1  PTV 
Tables 3.11 and 3.12 summarize the results in the PTV for each patient. There was a 
statistically significant difference between the modalities in mean dose to the PTV (p = 0.003). 
The average values for VMAT and HT plans were 52.0 ± 0.1 Gy and 51.5 ± 0.1 Gy, respectively. 
The HT plans showed a lower maximum dose to the PTV, with the value of 53.4 ± 0.1 Gy 
compared with 54.0 ± 0.2 Gy in VMAT (p = 0.01). The HT plans showed a statistical advantage 
in both PTV dose coverage metrics. The average minimum dose was 46.6 ± 0.3 Gy in VMAT to 
48.6 ± 0.2 Gy in HT (p < 0.001). The dose to 95% of the PTV was 49.3 ± 0.1 Gy in VMAT 
compared with to 49.8 ± 0.1 Gy (p < 0.001). VMAT achieved a significantly higher CI, with an 
average value of 0.778 ± 0.008 compared with 0.719 ± 0.008 in the HT plans (p < 0.001). 
However, HT achieved a significant improvement in DHI. The average DHI in the HT plans was 
0.096 ± 0.005 compared with 0.147 ± 0.009 in VMAT (p < 0.001). Both modalities achieved 
nearly 100% tumor control.  
3.3.2  Lungs 
Tables 3.13 and 3.14 contain a summary of the results in the lungs for each patient. V20Gy 
was 1.3 Gy lower on average in the HT plans, representing a statistically significant difference (p 
< 0.001). The maximum dose to the lungs was also significantly lower in the HT plans, with an 
average of 44.1 ± 0.5 Gy compared with 48.0 ± 0.5 Gy in VMAT (p < 0.001). However, the 
mean dose to the lungs was significantly lower in the VMAT plans. The average value was 12.7 
± 0.3 Gy in HT compared with 11.7 ± 0.3 Gy in VMAT (p = 0.01). The low-dose volumes were 
both significantly lower in the VMAT plans. An average of 89.8 ± 1.4% of the volume of the 
lungs in the HT plans received greater than 5 Gy, while only 66.2 ± 3.1% received this dose in 
the VMAT plans (p < 0.001). 45.9 ± 3.0% of the lungs received greater than 10 Gy in HT, while  
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Table 3.11: Evaluation metrics for the PTV 
Patient 
Dmean (Gy) Dmax (Gy) Dmin (Gy) D95% (Gy) 
VMAT HT VMAT HT VMAT HT VMAT HT 
11-001 52.3 51.3 54.7 53.2 46.2 48.5 49.2 50.0 
11-002 52.4 51.8 54.7 53.2 45.9 48.3 49.1 49.8 
11-003 52.4 51.3 54.8 53.4 46.7 48.6 49.4 50.0 
11-004 52.0 51.3 54.2 53.2 47.2 49.0 49.3 50.0 
11-005 52.6 51.5 55.2 53.9 45.9 48.7 49.1 50.0 
11-006 52.0 51.4 54.1 53.2 46.2 48.9 49.2 49.9 
11-007 52.4 51.4 54.8 53.5 45.1 48.7 48.8 49.9 
11-008 51.6 51.4 53.2 53.2 46.8 48.9 49.4 49.9 
11-009 51.6 52.1 53.2 54.3 47.0 48.6 49.4 49.7 
11-010 51.8 51.3 53.6 52.9 47.6 49.4 49.5 50.0 
11-011 52.2 51.5 54.3 53.9 46.1 48.5 49.0 49.8 
11-012 51.8 51.1 53.8 52.5 46.3 48.7 49.3 50.0 
11-013 51.1 51.2 52.5 52.7 48.3 48.3 49.7 49.7 
11-014 52.1 52.5 54.4 54.6 45.7 46.5 48.9 48.9 
11-015 51.4 51.3 52.8 53.2 48.6 48.9 49.9 50.1 
Mean 52.0 ± 0.1 51.5 ± 0.1 54.0 ± 0.2 53.4 ± 0.1 46.6 ± 0.3 48.6 ± 0.2 49.3 ± 0.1 49.8 ± 0.1 
p-value 0.003 0.01 < 0.001 < 0.001 
 
Table 3.12: Evaluation metrics for the PTV 
Patient 
CI DHI TCP (%) 
VMAT HT VMAT HT VMAT HT 
11-001 0.785 0.772 0.169 0.093 99.8 100.0 
11-002 0.781 0.729 0.175 0.097 99.9 100.0 
11-003 0.773 0.700 0.161 0.095 99.9 100.0 
11-004 0.807 0.743 0.139 0.085 100.0 100.0 
11-005 0.732 0.707 0.184 0.103 99.9 100.0 
11-006 0.737 0.675 0.158 0.087 99.8 100.0 
11-007 0.780 0.709 0.192 0.096 99.7 100.0 
11-008 0.760 0.745 0.127 0.085 100.0 100.0 
11-009 0.739 0.696 0.124 0.113 99.9 100.0 
11-010 0.789 0.709 0.119 0.070 99.4 100.0 
11-011 0.774 0.755 0.164 0.108 99.9 100.0 
11-012 0.800 0.713 0.149 0.076 99.5 100.0 
11-013 0.805 0.709 0.084 0.087 100.0 100.0 
11-014 0.760 0.665 0.172 0.160 99.8 100.0 
11-015 0.844 0.761 0.082 0.085 99.9 100.0 
Mean 0.778 ± 0.008 0.719 ± 0.008 0.147 ± 0.009 0.096 ± 0.005 99.8 ± 0.2 100.0 ± 0.0 
p-value < 0.001 < 0.001 0.002 
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Table 3.13: Evaluation metrics for the lungs 
Patient 
V20Gy (%) Dmean (Gy) Dmax (Gy) 
VMAT HT VMAT HT VMAT HT 
11-001 16.7 16.3 11.8 14.7 45.9 44.2 
11-002 16.0 14.8 11.9 12.2 49.4 46.9 
11-003 15.7 14.0 11.0 12.4 49.0 44.3 
11-004 16.9 12.8 12.3 11.1 45.4 41.0 
11-005 16.5 15.6 11.9 12.7 50.8 44.8 
11-006 15.7 14.5 11.1 12.4 50.4 45.6 
11-007 16.0 14.4 12.5 12.8 46.2 42.3 
11-008 16.7 15.7 11.3 13.2 50.0 47.6 
11-009 16.4 16.3 9.8 13.0 48.2 44.1 
11-010 14.4 13.5 10.0 11.0 46.9 45.0 
11-011 16.9 16.3 11.4 13.8 48.7 42.8 
11-012 15.6 15.7 11.0 12.8 48.1 44.2 
11-013 16.2 15.6 12.0 13.3 45.6 44.7 
11-014 17.4 16.3 13.5 13.5 49.4 43.6 
11-015 17.0 13.5 13.4 11.7 45.9 41.0 
Mean 16.3 ± 0.2 15.0 ± 0.3 11.7 ± 0.3 12.7 ± 0.3 48.0 ± 0.5 44.1 ± 0.5 
p-value < 0.001 0.01 < 0.001 
 
Table 3.14: Evaluation metrics for the lungs 
Patient 
V5Gy (%) V10Gy (%) NTCP (%) SCCP (%) 
VMAT HT VMAT HT VMAT HT VMAT HT 
11-001 68.9 95.7 38.8 69.6 0.3 1.6 5.5 6.4 
11-002 69.4 86.2 34.6 40.0 0.4 0.4 5.3 5.9 
11-003 58.1 93.2 29.9 40.8 0.2 0.4 5.1 6.2 
11-004 78.6 92.9 38.3 29.9 0.4 0.2 5.7 6.1 
11-005 67.7 89.0 31.9 43.3 0.4 0.5 5.4 6.1 
11-006 58.0 88.3 29.1 38.5 0.2 0.4 5.1 6.1 
11-007 86.7 94.1 41.9 47.4 0.5 0.5 6.0 6.3 
11-008 57.7 87.6 32.0 47.6 0.2 0.7 5.1 6.1 
11-009 43.4 85.8 27.3 48.4 0.1 0.6 3.8 6.0 
11-010 52.0 76.7 28.0 29.1 0.1 0.2 4.8 5.8 
11-011 59.5 89.2 32.7 62.4 0.3 1.0 5.1 6.2 
11-012 58.5 85.4 31.7 51.6 0.2 0.5 5.2 6.1 
11-013 78.1 98.9 36.3 48.5 0.3 0.7 5.7 6.3 
11-014 76.0 90.7 54.8 58.7 0.9 0.8 5.7 6.2 
11-015 80.0 94.0 53.9 33.1 0.8 0.2 5.9 6.2 
Mean 66.2 ± 3.1 89.8 ± 1.4 36.1 ± 2.2 45.9 ± 3.0 0.3 ± 0.1 0.6 ± 0.1 5.3 ± 0.1 6.1 ± 0.0* 
p-value < 0.001 0.01 0.06 < 0.001 
* Standard deviation of the mean < 0.05 
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only 36.1 ± 2.2% received this dose in VMAT (p = 0.01). The calculated NTCP values were 
lower for VMAT, but 
the difference was insignificant. VMAT showed a significantly lower SCCP, with an average 
value of 6.1 ± 0.0% in HT compared with 5.3 ± 0.1% in VMAT (p < 0.001).  
3.3.3  Heart 
Dose to the heart is more of a concern for left CW patients due to the proximity of the 
heart to the PTV. Consequently, results for the heart were divided into left and right CW 
patients.  
3.3.3.1  Left CW Patients 
A summary of results in the heart for each left CW patient can be found in Table 3.15 and 
3.16. The mean value of V30Gy was lower in the HT plan, with a value of 5.9 ± 0.7 Gy in VMAT 
compared with 4.8 ± 0.7 Gy. However, due to the large range of values in the two modalities—
1.6-7.5 Gy in VMAT and 1.2-7.5 Gy in HT—this difference was not 
statistically significant (p = 0.1). VMAT achieved lower mean dose to the heart, with an average 
of 12.9 ± 0.5 Gy compared with 14.4 ± 0.6 Gy in the HT plans (p = 0.04). The maximum dose 
was significantly lower in the HT plans, with an average value of 38.3 ± 1.3 Gy compared with 
42.2 ± 1.6 Gy in VMAT (p = 0.001). The low-dose volumes were lower in the VMAT plans, but 
the difference in V15Gy was insignificant (p = 0.4). The entire volume of the heart received 
greater than 5 Gy in the HT plans, while only 91.3 ± 3.6% received this dose in VMAT (p = 
0.04). NTCP was significantly lower in the HT plans, with an average of 0.9 ± 0.1% compared 
with 1.3 ± 0.2% in VMAT (p = 0.008).  
3.3.3.2  Right CW Patients 
Tables 3.17 and 3.18 contain a summary of the results in the heart for each right CW 
patient. V30Gy was lower in the VMAT plans, but the difference was insignificant (p = 0.07). The  
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Table 3.15: Evaluation metrics for the heart – left CW patients 
Patient 
V30Gy (%) Dmean (Gy) Dmax (Gy) 
VMAT HT VMAT HT VMAT HT 
11-002 4.8 4.6 14.5 14.6 42.6 40.2 
11-003 6.8 7.5 12.9 16.2 44.1 40.8 
11-004 1.6 1.2 12.1 12.0 31.7 30.8 
11-005 7.5 4.3 15.5 15.0 43.6 38.0 
11-006 6.7 6.6 12.9 15.3 45.5 41.6 
11-009 7.1 3.4 11.7 14.9 44.8 37.0 
11-010 6.0 3.9 11.0 11.2 40.3 36.2 
11-012 6.4 6.8 12.6 15.7 44.8 41.9 
Mean 5.9 ± 0.7 4.8 ± 0.7 12.9 ± 0.5 14.4 ± 0.6 42.2 ± 1.6 38.3 ± 1.3 
p-value 0.1 0.04 0.001 
 
Table 3.16: Evaluation metrics for the heart – left CW patients 
Patient 
V5Gy (%) V15Gy (%) NTCP (%) 
VMAT HT VMAT HT VMAT HT 
11-002 100.0 100.0 29.4 25.9 1.095 0.882 
11-003 91.1 100.0 25.7 36.6 1.530 1.327 
11-004 94.6 99.9 21.7 18.0 0.267 0.208 
11-005 100.0 100.0 37.6 33.3 1.566 0.778 
11-006 96.5 100.0 25.3 33.1 1.662 1.232 
11-009 75.8 100.0 22.6 29.6 1.624 0.566 
11-010 75.5 99.9 21.7 16.8 1.028 0.573 
11-012 96.8 100.0 24.0 32.5 1.558 1.293 
Mean 91.3 ± 3.6 100.0 ± 0.0* 26.0 ± 1.9 28.2 ± 2.6 1.3 ± 0.2 0.9 + 0.1 
p-value 0.04 0.4 0.008 
• Standard deviation of the mean < 0.05 
 
mean and maximum doses, however, were significantly lower in the VMAT plans. The mean 
dose was 12.4 ± 0.6 Gy in HT compared with 10.0 ± 0.5 Gy in VMAT (p = 0.02) and the 
maximum was 35.4 ± 2.6 Gy in HT compared with 27.2 ± 1.4 Gy in VMAT (p = 0.01). The low-
dose volumes were each lower in the VMAT plans. The average V5Gy in VMAT was 85.0 ± 4.1 
Gy compared with 90.6 ± 4.0 Gy in HT (p = 0.03), but the difference in V15Gy was insignificant 
(p = 0.09). NTCP in VMAT was lower by half, on average, but this difference was also 
insignificant (p = 0.08) due to the large range of values in the HT plans (0.1-1.2%).  
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Table 3.17: Evaluation metrics for the heart – right CW patients 
Patient 
V30Gy (%) Dmean (Gy) Dmax (Gy) 
VMAT HT VMAT HT VMAT HT 
11-001 0.1 4.3 8.9 14.4 25.4 41.3 
11-007 1.2 5.7 10.9 13.7 30.5 42.2 
11-008 1.0 1.5 10.0 12.4 30.0 31.7 
11-011 1.0 2.6 8.6 10.0 30.0 37.0 
11-013 0.5 0.7 11.6 12.4 28.4 42.2 
11-014 0.0 0.5 8.8 12.8 19.9 27.1 
11-015 0.4 0.4 11.4 11.1 26.2 26.5 
Mean 0.6 ± 0.2 2.2 ± 0.8 10.0 ± 0.5 12.4 ± 0.6 27.2 ± 1.4 35.4 ± 2.6 
p-value 0.07 0.02 0.01 
 
Table 3.18: Evaluation metrics for the heart – right CW patients 
Patient 
V5Gy (%) V15Gy (%) NTCP (%) 
VMAT HT VMAT HT VMAT HT 
11-001 77.4 94.5 11.9 37.3 0.1 0.9 
11-007 85.9 87.9 20.1 34.5 0.2 1.2 
11-008 82.8 87.4 16.6 26.5 0.2 0.3 
11-011 66.3 69.3 12.9 17.6 0.2 0.5 
11-013 97.6 100.0 19.4 15.9 0.1 0.1 
11-014 90.2 95.0 6.5 29.0 0.0 0.1 
11-015 94.6 100.0 20.3 13.3 0.1 0.1 
Mean 85.0 ± 4.1 90.6 ± 4.0 15.4 ± 2.0 24.9 ± 3.6 0.1 ± 0.0* 0.5 ± 0.2 
p-value 0.03 0.09 0.08 
* Standard deviation of the mean < 0.05 
3.3.4  Contralateral Breast 
Table 3.19 contains a summary of the evaluation metrics for the contralateral breast in the 
eleven patients who received a unilateral mastectomy. The results were comparable for both 
modalities, but the differences in mean dose and SCCP were statistically significant. Mean dose 
in the VMAT plans was 1.5 ± 0.1 Gy compared with 1.8 ± 0.1 Gy in HT (p < 0.001), and SCCP 
was 1.0 ± 0.0% in the VMAT plans compared with 1.2 ± 0.0% in HT (p < 0.001).  
3.3.5  Normal Tissue 
A summary of the evaluation metrics for normal tissue can be found in  
Table 3.20. There was a statistically significant reduction for every metric in the VMAT 
plans. The mean dose to normal tissue in the VMAT plans was 7.0 ± 0.2 Gy compared with 
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Table 3.19: Evaluation metrics for the contralateral breast 
Patient 
Dmean (Gy) Dmax (Gy) V5Gy (%) SCCP (%) 
VMAT HT VMAT HT VMAT HT VMAT HT 
11-001 1.6 2.1 4.4 5.6 0.4 1.8 1.0 1.4 
11-002 1.5 1.6 4.1 3.1 0.2 0.0 1.0 1.1 
11-003 1.2 1.5 3.5 3.3 0.0 0.1 0.8 1.0 
11-005 1.8 2.0 4.8 4.7 0.8 0.8 1.2 1.3 
11-006 1.3 1.5 4.0 3.4 0.3 0.1 0.9 1.0 
11-007 1.6 1.9 5.0 5.2 1.0 1.3 1.0 1.2 
11-008 1.5 1.7 3.5 3.4 0.0 0.0 1.0 1.1 
11-009 1.0 1.7 3.6 2.8 0.0 0.1 0.7 1.1 
11-011 1.5 1.9 4.0 3.1 0.0 0.1 1.0 1.2 
11-012 1.4 1.7 4.1 3.5 0.1 0.1 1.0 1.1 
11-014 1.8 2.3 4.4 5.4 0.3 1.5 1.2 1.5 
Mean 1.5 ± 0.1 1.8 ± 0.1 4.1 ± 0.1 4.0 ± 0.3 0.3 ± 0.1 0.5 ± 0.2 1.0 ± 0.0* 1.2 ± 0.0* 
p-value < 0.001 0.5 0.2 < 0.001 
* Standard deviation of the mean < 0.05 
 
Table 3.20: Evaluation metrics for normal tissue 
Patient 
Dmean (Gy) Dmax (Gy) SCCP (%) 
VMAT HT VMAT HT VMAT HT 
11-001 6.8 10.4 41.1 43.8 0.8 1.0 
11-002 6.3 10.3 40.5 43.6 0.5 0.7 
11-003 8.1 12.7 42.4 46.8 0.9 1.0 
11-004 8.4 12.8 39.4 42.8 0.9 1.0 
11-005 7.2 11.5 44.1 43.4 0.6 0.7 
11-006 7.9 12.6 43.9 46.0 0.6 0.8 
11-007 8.2 11.2 42.9 43.9 0.8 1.0 
11-008 5.3 9.6 42.9 42.6 0.4 0.5 
11-009 6.2 11.6 43.2 42.0 0.6 0.9 
11-010 7.0 10.7 40.5 41.5 0.6 0.8 
11-011 5.7 8.7 42.8 39.4 0.6 0.8 
11-012 8.0 13.6 44.0 45.9 0.9 1.1 
11-013 6.5 10.1 40.5 42.2 0.6 0.7 
11-014 6.8 10.2 39.0 41.2 0.8 1.0 
11-015 7.1 10.1 37.9 41.5 0.9 1.0 
Mean 7.0 ± 0.2 11.1 ± 0.4 41.7 ± 0.5 43.1 ± 0.5 0.7 ± 0.0* 0.9 ± 0.0* 
p-value < 0.001 0.02 < 0.001 
* Standard deviation of the mean < 0.05 
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11.1 ± 0.4 Gy in HT (p < 0.001). Maximum dose was lower in VMAT, with an average value of 
41.7 ± 0.5 Gy compared with 43.1 ± 0.5 Gy in HT (p = 0.02). SCCP in VMAT was significantly 
lower than HT (p < 0.001), but both modalities achieved less than 1%.  
3.3.6  Delivery Efficiency 
Table 3.21 contains a summary of the results for delivery efficiency. VMAT delivery 
times for each patient are reported as mean and one standard deviation, while the HT times were 
taken from the plan report and do not have a known experimental uncertainty. Consistent with 
the results reported for the individual patients, the delivery times in VMAT were significantly 
shorter than in HT. VMAT delivery time was shorter by an average of 66.2%. The average 
delivery time for VMAT was 2.1 minutes compared with 6.4 minutes in HT (p < 0.001). 
Table 3.21: Delivery efficiency results 
Patient 
Delivery Time (s) 
VMAT HT 
11-001 128.2 ± 4.2 379.4 
11-002 126.4 ± 1.3 379.8 
11-003 130.5 ± 1.6 391.9 
11-004 126.7 ± 1.8 380.1 
11-005 130.3 ± 0.6 360.0 
11-006 126.1 ± 1.3 361.4 
11-007 130.2 ± 1.6 378.7 
11-008 132.8 ± 6.9 352.6 
11-009 132.2 ± 3.3 490.7 
11-010 125.7 ± 2.1 317.3 
11-011 128.8 ± 3.5 436.5 
11-012 125.0 ± 1.6 418.7 
11-013 130.5 ± 1.2 358.6 
11-014 129.3 ± 1.7 393.5 
11-015 126.2 ± 1.8 336.8 
Mean 128.6 ± 2.8 382.4 ± 10.9 
p-value < 0.001 
3.3.7   Unilateral vs. Bilateral Mastectomy 
For those patients who received a bilateral mastectomy (N = 4), there were systematic 
improvements in the PTV results for both modalities over those who received a unilateral 
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mastectomy (N = 11). Table 3.22 and Table 3.23 show the mean values and one standard 
deviation of the mean for the comparison results between the two groups for each modality. The 
improvements, however, were only statistically significant in the VMAT plans. Mean, maximum 
and minimum doses, dose to 95%, CI and DHI all showed significant improvements in the 
VMAT plans for those patients who received a bilateral mastectomy compared with those who 
received a unilateral mastectomy.  
Table 3.22: Comparison between unilateral and bilateral mastectomy for the PTV 
 
Dmean (Gy) Dmax (Gy) Dmin (Gy) D95% (Gy) 
VMAT HT VMAT HT VMAT HT VMAT HT 
Unilateral 52.1 ± 0.1 51.6 ± 0.1 54.3 ± 0.2 53.5 ± 0.2 46.2 ± 0.2 48.4 ± 0.2 49.2 ± 0.1 49.8 ± 0.1 
Bilateral 51.6 ± 0.2 51.3 ± 0.0* 53.3 ± 0.4 53.0 ± 0.1 47.9 ± 0.3 48.9 ± 0.2 49.6 ± 0.1 50.0 ± 0.1 
p-value 0.02 0.2 0.03 0.1 < 0.001 0.2 0.003 0.4 
* Standard deviation of the mean < 0.05 
Table 3.23: Comparison between unilateral and bilateral mastectomy for the PTV 
 
CI DHI TCP (%) 
VMAT HT VMAT HT VMAT HT 
Unilateral 0.766 ± 0.007 0.715 ± 0.010 0.161 ± 0.006 0.101 ± 0.007 99.8 ± 0.0* 100.0 ± 0.0 
Bilateral 0.811 ± 0.012 0.731 ± 0.013 0.106 ± 0.014 0.082 ± 0.004 99.8 ± 0.1 100.0 ± 0.0 
p-value 0.004 0.4 0.001 0.1 0.4 – 
*Standard deviation of the mean < 0.05 
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Chapter 4:  Discussion 
The first question addressed by this study was whether VMAT is capable of generating 
clinically acceptable treatment plans for PMRT. Nearly all of the dosimetric planning goals were 
met in the VMAT plans for each of the 15 patients in this study. One treatment plan was unable 
to meet the goals for maximum PTV dose and the dose to 20% of the heart, and three failed to 
meet the goal for minimum PTV dose. However, these goals were meant to be conservative, and 
a radiation oncologist deemed each of these plans clinically acceptable. Furthermore, all 15 
VMAT plans achieved nearly 100% tumor control, less than 1% NTCP in the lungs and less than 
2% NTCP in the heart.  
The second objective of this study was to compare dual-arc VMAT treatment plans with 
HT plans using a 4.98 cm field width for PMRT on the basis of dosimetric quality, 
radiobiological calculations and delivery efficiency. Contrary to the hypothesis, the two 
modalities showed significant differences (p < 0.05) in many comparison metrics. However, 
neither modality performed better in all metrics where significant differences were observed.  
VMAT plans showed significantly better PTV conformity. This finding is consistent with 
that of Rong et al. (2011), who found VMAT capable of superior PTV conformity in head and 
neck treatment plans. Most HT plans in this study contained a region posterior to the lateral 
portion of the PTV receiving the prescription dose or greater. This region of overdose lowered CI 
in the HT plans. A possible explanation for their existence is the limit on superior-inferior 
resolution due to the 4.98 cm field width used for this study. This limitation results in a more 
gradual dose falloff immediately superior and inferior to the PTV, but it is unclear if, and how 
this might affect the dose posterior to the PTV. Future studies might investigate decreasing the 
field width from 5 to 2.5 cm for PMRT. However, as shown in the study by Moldovan et al. 
(2011), this change will result in a reduction in delivery efficiency.  
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HT treatment plans showed significantly better PTV dose homogeneity and coverage. 
Similarly, Clemente et al. (2011) showed HT is capable of superior dose homogeneity and 
coverage for oropharyngeal treatment plans. In the current study, DHI was 35% lower, on 
average, in HT than in VMAT. Along with greater homogeneity, the minimum and maximum 
doses to the PTV were significantly better in the HT plans.  
Results outside the PTV were mixed. VMAT achieved significantly smaller low-dose 
volumes in the lungs and heart, and lower mean doses to the lungs, heart, contralateral breast and 
normal tissue. This observation may be attributed to the 220-degree arcs used in VMAT. While 
the HT plans deliver dose over the entire 360-degree, delivery in the VMAT plans was limited to 
the angles selected, thus eliminating much of the integral dose seen in HT. This is especially 
important for younger patients, whose long-term survival might be dependent on limiting 
integral dose as much as possible. According to Hancock et al. (1993), women under the age of 
30 are at much higher risk for radiation-induced breast cancer after treatment for Hodgkin’s 
disease. Previous studies by Rao et al. (2010), Rong et al. (2011) and Clemente et al. (2011) 
showed mixed results for these metrics; however, full arcs were used in the VMAT plans in these 
studies. Efforts were made throughout this study to match the clinical practice at this facility, and 
it was for this reason furthers steps to match this limited delivery geometry were not taken for 
the HT plans. However, future studies might investigate the use of directional-blocking 
structures in HT in order to mimic this 220-degree delivery.  
On the other hand, V20Gy and the maximum dose to the lungs, and the maximum dose to 
the heart in left CW patients were all significantly lower in the HT plans. These findings, along 
with evidence in the isodose distributions, suggest that HT is capable of higher dose gradients 
surrounding the PTV than VMAT. The close proximity of the lungs and heart (for left CW 
patients) to the PTV requires the treatment plan to drastically reduce dose from its level in the 
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PTV to a much lower level over a very small distance. Treatment planning optimization involves 
weighing objectives and making decisions based on input from the user to generate the most 
desirable plan. This often requires compromising results for different metrics. It is possible that 
the improved dose gradient in the region of the lungs and heart may have resulted in the region 
of overdose posterior to the PTV that caused the reduction in CI seen in the HT plans.  
VMAT and HT both achieved nearly 100% tumor control and approximately 1% NTCP 
in the lungs and heart, but the calculated values for SCCP were significantly lower in the VMAT 
plans for every structure evaluated (lungs, contralateral breast and normal tissue). As a function 
of organ equivalent dose (OEDorg), SCCP is heavily dependent on mean dose to the volume, 
which was lower for every OAR in the VMAT plans. SCCP results represent lifetime risk, with a 
mean residual lifetime of 50 years. As previously discussed, this finding is especially important 
for younger patients, whose longer residual lifetime puts them at greater risk for therapeutic 
radiation-induced secondary cancers.  
Homogeneity and TCP in VMAT were superior to the conventional mixed-beam 
technique studied by Ashenafi et al. (2010). However, like the HT plans in the previous study, 
VMAT delivered higher doses to OARs and normal tissue than the mixed-beam plans. Results 
for the HT plans in the current study were comparable to the HT plans of the previous, with a 
few exceptions: HT plans in the current study showed higher TCP, as well as lower mean dose, 
V5Gy and SCCP in the heart; but higher V20Gy in the lungs and V15Gy in the heart than the HT 
plans in the previous study. The differences in the HT plans are likely attributable to the 4.98 cm 
field width used in this study, as the previous study used a field width of 2.5 cm.  
An unexpected finding of this study was the improvement seen in those patients who 
received a bilateral mastectomy compared with those who received a unilateral mastectomy. This 
can most likely be attributed to an increase in degrees of freedom. The medial border of the 
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contralateral breast ROI is the closest OAR to the PTV, and in the VMAT plans, consistently 
resulted in the highest objective value. With this obstacle removed, VMAT is capable of DHI 
comparable to that in HT. The fact that these improvements were only statistically significant in 
the VMAT plans further supports the conclusion that HT is capable of higher dose gradients 
surrounding the PTV than VMAT.  
The final goal of this study was to compare the two modalities on the basis of delivery 
efficiency. As expected, VMAT showed a significant advantage over HT. The 66% lower 
treatment times in VMAT for this study were consistent with results by Rong et al. (2010) and 
Rao et al. (2011), who showed VMAT is capable of delivering treatment 50% and 70% faster 
than HT, respectively. The geometry in VMAT lends itself to faster delivery, as it is able to 
cover the entire target in just one arc. However, TomoTherapy linear accelerators have higher 
gantry rotation speeds than traditional linear accelerators. They are capable of a maximum of 
five rotations per minute, while traditional accelerators are limited to one rotation per minute. 
Despite faster rotation, the helical nature of dose delivery is inherently slow. Steps have been 
taken to maximize delivery efficiency in HT, specifically by the adoption of a 4.98 cm field 
width at our clinic, but despite these steps, the mean treatment time in VMAT for this study was 
a factor of three times faster than HT.  This is important for both the clinic and the patient; 
shorter treatment time allows for greater flexibility in scheduling and facilitates treating more 
patients in a day; and can lead to improved patient comfort, and a lower risk of intrafractional 
movement.  
 55 
Chapter 5:  Conclusion 
This study demonstrated that dual-arc VMAT is capable of generating clinically 
acceptable treatment plans for PMRT. VMAT plans showed better conformity in the PTV and 
better low-dose OAR sparing in the lungs, heart and normal tissue. On the other hand, HT plans 
showed better dose homogeneity and coverage in the PTV and better OAR sparing at higher 
doses. The smaller volume of OARs and normal tissue receiving low doses in the VMAT plans 
led to lower predicted SCCP for the lungs, contralateral breast and normal tissue. Both VMAT 
and HT plans achieved nearly 100% tumor control and approximately 1% NTCP in the lungs and 
heart. The major advantage of VMAT over HT is the shorter treatment time. In conclusion, due 
to the ability of VMAT to generate highly conformal and efficient PMRT treatment plans that 
are clinically comparable to HT, this study recommends VMAT be considered as a viable option 
for PMRT. 
Future studies should investigate optimization of other VMAT delivery parameters, such 
as arc length and number of arcs. For HT, directional blocking structures might be used to mimic 
the 220-degree delivery of VMAT. Further investigation into methods to reduce integral dose are 
suggested, especially for patients younger than 30 years of age. Finally, dosimetric and in-vivo 
dose verification should be performed, as well as a clinical evaluation of patient outcomes for 
PMRT patients treated with VMAT.  
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Figure A.1: Isodose distributions for patient 11-001 showing VMAT (a) and HT (b) plans in 





Figure A.2: Isodose distributions for patient 11-001 showing VMAT (a) and HT (b) plans in 





Figure A.3: Isodose distributions for patient 11-002 showing VMAT (a) and HT (b) plans in 





Figure A.4: Isodose distributions for patient 11-002 showing VMAT (a) and HT (b) plans in 





Figure A.5: Isodose distributions for patient 11-004 showing VMAT (a) and HT (b) plans in 





Figure A.6: Isodose distributions for patient 11-004 showing VMAT (a) and HT (b) plans in 





Figure A.7: Isodose distributions for patient 11-005 showing VMAT (a) and HT (b) plans in 





Figure A.8: Isodose distributions for patient 11-005 showing VMAT (a) and HT (b) plans in 





Figure A.9: Isodose distributions for patient 11-006 showing VMAT (a) and HT (b) plans in 





Figure A.10: Isodose distributions for patient 11-006 showing VMAT (a) and HT (b) plans in 





Figure A.11: Isodose distributions for patient 11-007 showing VMAT (a) and HT (b) plans in 





Figure A.12: Isodose distributions for patient 11-007 showing VMAT (a) and HT (b) plans in 





Figure A.13: Isodose distributions for patient 11-008 showing VMAT (a) and HT (b) plans in 





Figure A.14: Isodose distributions for patient 11-008 showing VMAT (a) and HT (b) plans in 





Figure A.15: Isodose distributions for patient 11-009 showing VMAT (a) and HT (b) plans in 





Figure A.16: Isodose distributions for patient 11-009 showing VMAT (a) and HT (b) plans in 





Figure A.17: Isodose distributions for patient 11-010 showing VMAT (a) and HT (b) plans in 





Figure A.18: Isodose distributions for patient 11-010 showing VMAT (a) and HT (b) plans in 





Figure A.19: Isodose distributions for patient 11-011 showing VMAT (a) and HT (b) plans in 





Figure A.20: Isodose distributions for patient 11-011 showing VMAT (a) and HT (b) plans in 




Figure A.21: Isodose distributions for patient 11-012 showing VMAT (a) and HT (b) plans in 





Figure A.22: Isodose distributions for patient 11-012 showing VMAT (a) and HT (b) plans in 





Figure A.23: Isodose distributions for patient 11-014 showing VMAT (a) and HT (b) plans in 





Figure A.24: Isodose distributions for patient 11-014 showing VMAT (a) and HT (b) plans in 





Figure A.25: Isodose distributions for patient 11-015 showing VMAT (a) and HT (b) plans in 





Figure A.26: Isodose distributions for patient 11-015 showing VMAT (a) and HT (b) plans in 
transverse slice — designated by yellow line in sagittal view (c) — located in 
supraclavicular region
 85 
Appendix B: Dose Volume Histograms 
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